EUVIMEDEUVIMED entdecken
Crossref

Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers

Wenhua Zhang, Beixuan He, Lei Zhang, Zixin Li, Meilin Ma, Jiaying Xie, Xinyu Wang, Zhen Fang, Zhuying Yue, Ziru Xue, Ning Tang, Jie Li und 3 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Wenhua Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China; Department of Biliary-Pancreati…. Hauptthemen laut MEDLINE: Sorafenib, Energy Metabolism, Antineoplastic Agents, Cholangiocarcinoma. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Shanghai Rising-Star Program, Shanghai Jiao Tong University, Science and Technology Program of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biliary tract cancers (BTCs) comprise biologically heterogeneous subtypes with limited therapeutic options and variable responses to sorafenib. The biological basis underlying this variability remains unclear. In this study, we compared intrahepatic cholangiocarcinoma (iCCA) and gallbladder cancer (GBC) models under defined sorafenib exposure conditions using transcriptomic profiling, Seahorse-based mitochondrial stress assays, pharmacologic combination analysis, and patient-derived organoid models. In representative iCCA models, 1.25 μM sorafenib increased mitochondrial respiration and ATP production, whereas 10 μM sorafenib suppressed this respiratory adaptation. In contrast, representative GBC models exhibited persistent suppression of mitochondrial respiratory function across the tested conditions and did not display a comparable concentration-dependent shift. Integrated transcriptomic and pharmacologic analyses further identified mitochondrial Complex I as a treatment-relevant vulnerability under sorafenib exposure, with stronger combination interactions observed in iCCA models. These findings indicate that iCCA and GBC differ in their metabolic responses to sorafenib and highlight subtype-specific differences in mitochondrial adaptation under treatment stress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibEnergy MetabolismAntineoplastic AgentsCholangiocarcinomaBiliary Tract NeoplasmsGallbladder NeoplasmsHumansMetabolic ReprogrammingMitochondriaAnimalsCell Line, TumorGene Expression Profiling

Stichwörter der Autor:innen

Biliary tract cancersCombination therapyMetabolic adaptationMitochondrial functionSorafenib

Substanzen

SorafenibAntineoplastic Agents

Autor:innen und Institutionen

  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China; Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University…
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China; Shanghai Key Laboratory for Cancer…
  • National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201210, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affili…
  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China. Electronic address: yinziming1@163.com.

Förderung

  • Shanghai Rising-Star Program
  • Shanghai Jiao Tong University
  • Science and Technology Program of Guizhou Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., He, B., Zhang, L., Li, Z., Ma, M., Xie, J., Wang, X., Fang, Z., Yue, Z., Xue, Z., Tang, N., Li, J., Yin, Z., Li, Y., & Liu, Y. (2026). Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218700

Vancouver

Zhang W, He B, Zhang L, Li Z, Ma M, Xie J, et al. Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218700

BibTeX
@article{Zhang2026,
  author = {Zhang, Wenhua and He, Beixuan and Zhang, Lei and Li, Zixin and Ma, Meilin and Xie, Jiaying and Wang, Xinyu and Fang, Zhen and Yue, Zhuying and Xue, Ziru and Tang, Ning and Li, Jie and Yin, Ziming and Li, Yanjing and Liu, Yingbin},
  title = {Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218700}
}
Kostenlos starten →